New York, NY, March 3, 2010 – Small cap company profiles of Smokefree Innotec, Inc. (PINKSHEETS: SFIO) and ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC).
Smokefree Innotec, Inc. closed at $0.035 Tuesday, trading 2,449,615 shares.
Small cap company Smokefree Innotec Inc. signs contract to introduce product line to military.
President Thomas Schroepfer of Smokefree Innotec Inc. (OTC: SFIO) announced today that Leading Points Corporation of Centennial, Colorado has executed an agreement with the Company to develop an education, marketing and sales strategy for the military and government sector.
NASHVILLE, TN, Mar 02, 2010 -- Smokefree Innotec, Inc. (PINKSHEETS: SFIO)
About SmokeFree Innotec, Inc. (PinkSheets: SFIO)
Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing a hi-tech, nicotine delivery cigarette-like device which is completely smoke and vapor-free and tobacco-free. Smokefree Innotec's products are designed to protect the non-smoker from second hand smoke and all its effects while providing the smoker a way to enjoy a smoke-free cigarette anywhere, including places where smoking tobacco or similar substances is prohibited. Further, our products will allow the smoker to enjoy smoking while not having to worry about the offensive dangers and ill effects of regular cigarette smoking.
View SFIO penny stock news and charts free at StockProfiler.US! http://stockprofiler.us/?action=main.stock_quotes&symbol=SFIO
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
ImmunoCellular Therapeutics, Ltd. closed at $0.90 Tuesday, trading 26,340 shares.
ImmunoCellular Therapeutics Receives Notice of Allowance for a New Patent for its Antibody.
LOS ANGELES - March 2, 2010 - ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers.
About ImmunoCellular Therapeutics (IMUC)
IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma.
The small cap Company is planning to initiate a multicenter phase II study in the second half of 2010. The Company’s “off the shelf” therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the second half of 2010.
IMUC has entered into a research and license option deal with the Roche Group for one of the Company’s monoclonal antibody product candidates for the diagnosis and treatment of ovarian cancer and multiple myeloma, which provides for potential licensing and milestone payments of $32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications.
IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery to target cancer stem cells.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
StockProfiler.US Announcement!
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://stockprofiler.us/index.php?action=main.register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------
Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com, http://www.fastmoneytalk.com, http://www.markettelegraph.com, http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://stockprofiler.us/?action=main.disclaimer
-------------------------------------------
Keywords: sfio, sfio stock, sfio stock news, sfio stock alerts, sfio company news, sfio small cap stock, small cap news, small cap stock alerts, small cap stock updates, small cap stock news, small cap stock profile
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment